The nice people at Transfusion News sent their
update today. Three articles… I wish I could get my head round weak D and D
variants…
Daprodustat is Noninferior to Erythropoiesis-Stimulating Agents for Patients with Chronic Kidney Disease Undergoing Dialysis
 | | December 1, 2021 | | According
to the U.S. CDC, about 37 million adults in the United States have
chronic kidney disease (CKD). As CKD progresses, many patients require
dialysis and develop anemia, which is usually treated with blood
transfusions, erythropoiesis-stimulating agents (ESAs), and intravenous
iron. Previous clinical trials have linked ESA use, however, to
increased risk of stroke, myocardial infarction, thrombosis, and even
death when targeting a normal hemoglobin level (i.e., 13.0 to 14.0
g/dL). [Read More] |
|
 | | In
this new Transfusion Science Webinar, Sue Johnson, Director of Clinical
Education at Versiti and Director of the Transfusion Medicine Program
at Marquette University, will share the challenges faced by laboratory
scientists in typing for RhD and discuss strategies for detecting and
identifying weak and partial D variants. [Register Now] |
|
 | |
| November 22, 2021 | | Transfusion-associated
graft versus host disease (TA-GVHD) is a rare complication that occurs
when histoincompatible viable lymphocytes are transfused into an
immunocompromised individual. The transfused lymphocytes recognize the
recipient as foreign and mount an almost universally fatal immunological
response. Leukoreduction filters are not completely effective at
eliminating TA-GVHD; therefore, red blood cell components are irradiated
to prevent TA-GVHD. [Register Now] |
|
No comments:
Post a Comment